Business Context and Reporting Period
Company: BioRestorative Therapies, Inc. (NASDAQ: BRTX)
Filing Type: Form 8-K (Current Report)
Date of Report: June 13, 2025
Reporting Period: Single event date (June 13, 2025)
This filing serves as a Regulation FD disclosure regarding the presentation of new clinical data at the International Society for Stem Cell Research (ISSCR) 2025 Annual Meeting in Hong Kong.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a current report focused on a specific corporate event and does not contain financial statements or performance metrics.
Material Changes
No material financial changes are reported. The material event disclosed is the presentation of preliminary, blinded clinical data from approximately 30 patients enrolled in the ongoing Phase 2 trial of BRTX-100 for the treatment of chronic lumbar disc disease (cLDD).
Guidance, Outlook, and Management Commentary
- Clinical Update: Francisco Silva, Vice President of Research and Development, presented data titled "Stem Cell Therapy for Chronic Lumbar Disc Disease: Phase 2 Clinical Safety and Feasibility Data of Intradiscal Injections of Hypoxic Cultured Mesenchymal Stem Cells."
- Future Use of Data: The Company intends to use the presentation materials in future communications with investors, lenders, and other stakeholders.
- Disclaimer: The Company specifically disclaims any obligation to update the presentation materials in the future or to reflect events occurring after the date of this report.
- Availability: Presentation materials are furnished as Exhibit 99.2 and will be posted on the Company's website under "Scientific Publications" for 90 days.
Investor Verification Checklist
- Verify the specific clinical outcomes and safety data details in the attached Press Release (Exhibit 99.1) and Presentation Materials (Exhibit 99.2).
- Confirm the total number of patients enrolled in the Phase 2 trial versus the approximately 30 patients included in the preliminary data set.
- Review the Company's website (www.biorestorative.com) for the posted presentation materials within the 90-day window.
- Check subsequent filings for any updates or modifications to the clinical data presented.